Results 41 to 50 of about 35,256 (161)
Frontiers in Immunology, 2013 The remarkable clinical efficacy of anti-CD20 monoclonal antibodies (mAb) in relapsing-remitting multiple sclerosis (RRMS) points at the critical involvement of B cells in the disease.
Bert A 'T Hart +5 more
doaj +1 more source
Cellular Physiology and Biochemistry, 2013 Background: Rituximab, a mouse Fab and human Fc chimeric antibody, has been widely used to treat Non-Hodgkin's lymphoma (NHL). However, only 48% of patients respond to the treatment and complete response rate is below 10%.
Haifeng Zhang +5 more
doaj +1 more source
The clinical development of obinutuzumab for the treatment of follicular lymphoma
Cancer Management and Research, 2017 Barbara Ma,1 Chaitra Ujjani2 1Department of Medicine, 2Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC, USA Abstract: Impressive progress has been made in recent decades for advanced-stage follicular lymphoma ...
Ma B, Ujjani C
doaj
Therapeutic Advances in HematologySeveral clinical trials with anti-CD20 antibodies have successfully treated Acute Lymphoblastic Leukemia. Nevertheless, systematic comparisons between different anti-CD20 antibody trials are rare, and a comprehensive evaluation of their efficacy and ...
Xiaomei Zhou +5 more
doaj +1 more source
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance [PDF]
Oncogene, 2003 Rituximab, a chimeric monoclonal antibody targeted against the pan-B-cell marker CD20, was the first monoclonal antibody to be approved for therapeutic use. Treatment with rituximab at standard weekly dosing is effective in more than 50% of patients with relapsed or refractory CD20-positive follicular non-Hodgkin's lymphoma, but is not curative.
openaire +2 more sources
Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment
Autoimmunity Highlights, 2017 The clinical success of anti-CD20 monoclonal antibody (mAb)-mediated B cell depletion therapy has contributed to the understanding of B cells as major players in several autoimmune diseases. The first therapeutic anti-CD20 mAb, rituximab, is a murine-human chimera to which many patients develop antibodies and/or experience infusion-related reactions. A
Fanny Huynh Du +2 more
openaire +3 more sources
Role of ofatumumab in treatment of chronic lymphocytic leukemia
Journal of Blood Medicine, 2011 Marays Veliz, Javier Pinilla-IbarzH Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USAAbstract: The management of chronic lymphocytic leukemia (CLL) has dramatically improved in the past decade with the addition of anti-CD20 monoclonal ...
Veliz M, Pinilla-Ibarz J
doaj
Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia
Biologics: Targets & Therapy, 2015 Sonia Cerquozzi,1 Carolyn Owen2 1Department of Hematology, University of Calgary, 2Department of Hematology, Tom Baker Cancer Centre, Calgary, AB, Canada Abstract: The introduction of targeted therapy against CD20+ with the monoclonal antibody rituximab
Cerquozzi S, Owen C
doaj
Rituximab and Other New Anti-CD20 MAbs for Non-Hodgkin’s Lymphoma Treatment [PDF]
European Medical Journal Oncology, 2013 Non-Hodgkin’s lymphomas (NHLs) are a heterogeneous group of different haematological cancers with a wide range of aggressiveness. NHLs represent >80% of lymphomas and the majority of NHLs involve B cells.
Letizia Polito +4 more
doaj
Canadian Journal of Gastroenterology, 2013 BACKGROUND: Although most patients with autoimmune hepatitis (AIH) respond to treatment with prednisone and/or azathioprine, some patients are intolerant or refractory to standard therapy.
Kelly W Burak +7 more
doaj +1 more source